• Driving and executing the medical strategy for 3 First in Man clinical programs with disruptive therapies: TMVR, Mitral adjustable surgical ring, and artificial urinary sphincter. • Successful Pre Sub meeting with FDA for de novo submission• Building KOL network. Close interactions with scientific societies, meeting at the EU parliament. • Impactful presentations of interim data at PCR and key congresses. • Supporting Business development and interactions with investors ($15 Mio agreement with EW).

• Leading the Clinical Organization (team of 30+, 6 Mio € budget) including medical affairs, clinical operations, medical affairs, statistics, data management and safety• Setting strategic directions for interventional cardiology, PAD, and interventional oncology • Launch of Kansas stent, Roadsaver stent, CE mark submission of Nagomi stent• High volume of podium presentations at key congresses and publication in key journals• Strong interactions with KOLs, collaboration with Scientific Societies (e.g., ESC, PCR, CIRSE)• Collaborate closely with global teams in Japan and provide strategic direction for Life Cycle Mgt

• Setting up the new EU clinical operations organization across EMEA for the newly created TMTT BU• CE Mark approval for CardioBand Mitral and Tricuspid. CE Mark preparation for PASCAL.• Drive clinical strategy and operations across EMEA and Canada for innovative medical devices. • Leading a team of 20 + based in Switzerland, UK, Israel, Belgium and Germany.• Manage, engage, and develop top KOLs.• Support key affiliates in pre-launch activities and data dissemination.

• Leading the EU and US Clinical Affairs team. • Set up Global clinical strategy: launch of Resilia valve and support surgical valves business• Contribute to the Global regulatory strategy: direct interactions with the FDA and Market Access.

• Design and execute, clinical plan to support business in a competitive surgical valves market. • Support INTUITY valve penetration with numerous podium presentations and publications• Manage KOLs, review IIS proposal.• Support Clinical activities in China by meeting Chinese FDA and presentation at RA meeting.

• Joining the InterMune EU organization when the company was building up the EU team. • Support successfully market access in top 5 countries, meetings with authorities• Delivered strong publication plan: in total more than 25 articles and 7 abstracts.• Strong KOL network, organization of Ad Boards, and support of patients ‘associations.• Sept 2014: Acquisition of InterMune by Roche for $8 Billions.

• Driving the Global Med Affairs strategy for a new oral IP receptor agonist, selexipag (Phase III), • Support Market Access, Med Ed, KOL advocacy.

• Responsible for late-stage clinical trials and observational studies at HQ in Pulmonary Arterial Hypertension, Systemic Sclerosis and Niemann-Pick C. Member of Life Cycle Team.• Leading a team of 5 clinical scientists and 1 physician.

• Driving and implementing the global medical strategy for Tracleer (PAH)• Managing key opinion leaders, patients ‘associations and to coordinate plans and programs with other medical departments (act as a medical brand champion for the product).

Independent Expert at EU Commission - DG Research

• Regional Medical Director responsible for Belatacept: a new selective co-stimulation blocker currently in Phase III (Immunosuppressive therapy, Kidney Transplantation).

Contributor to local brand plans and strategies.Responsible for Post Marketing trial design, budget and planning. Support Medical Information, Advertising & Promotion.

In the global R&D team, responsible for the design and implementation of Phase IIIb / IV program in Allergy (levocetirizine). Responsible for the contents of Investigator’s Brochure, protocols, expert reports (i.e. QT issues with antihistamines) and responses to Regulatory Authority. Writing and reviewing Protocols, Patient informed consents, Literature reviews, CRFs.

Manager of a team of 10 Clinical Research Associates and 2 secretaries. Responsible for cardiovascular international and national Phase II to III studies with rosuvastatin, ximelagatran and candesartan. Member of the brand team.

Reporting to the Medical director and Business Unit Manager, direct collaboration with the product managers. Successful transition from clinical cardiology to pharmaceutical industry. Response to health authorities. Generate phase IV protocols for Aprovel